secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-12-15T23:59:59+00:00
Accession:  0001104659-23-126400
Event type: debt
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx amends Hercules loan, repays $1M; cash covenant lowered to $1.05M through Jan 2024
--------------------------------------------------------------------------------

- Minimum qualified cash reduced to $1.05M from Dec 15, 2023 to Jan 25, 2024.
- Company repaid $1.0M of principal; remaining Term Loan principal is $3.1M.
- After Jan 25, minimum cash reverts to $1.05M plus accounts payable unpaid over 180 days.
- Amendment provides temporary liquidity relief amid cash constraints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/0001104659-23-126400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923126400/tm2332971d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-126400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer